Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 155

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 155
---
 industry. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant
agencies, such as the FDA or the NIH to continue to function at current levels. Amounts allocated to federal grants and contracts may
be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and
development, manufacturing, and marketing activities which may delay our ability to develop, market and sell any products we may develop.

| 66 |

We expect additional
state, federal and foreign healthcare policies and reform measures to be adopted in the future, any of which could limit reimbursement
for healthcare products and services or otherwise result in reduced demand for our products or other products we may commercialize in
the future or additional pricing pressure and have a material adverse effect on our industry generally and on our customers. Any changes
in, or uncertainty with respect to, future coverage or reimbursement rates could affect demand for our products or other products we may
commercialize in the future, which, in turn, could impact our ability to successfully commercialize our products or other products we
may commercialize in the future and could have a material adverse effect on our business, financial condition and results of operations.

We may not comply with
all of the material terms of the licenses under which our technology has been acquired or supply agreements pursuant to which components
of our products are supplied, which may require us to expend resources to regain compliance and which may adversely impact our results
of operations.

Certain of our
technology is licensed to the Targets from third parties pursuant to various technology license agreements (see “Information about
Longevity — License Arrangements”) that contain provisions relating to, among other things, royalty payments on net sales
of products utilizing the licensed technology, minimum royalty payments, milestones triggering one-time payments, other payments and fees,
and other obligations to the licensors. In addition, we obtain components of our products pursuant to supply agreements that may also
contain product development milestones. If we do not comply with the material terms of these agreements, we may be materially adversely
affected if the licensors or other counterparties exercise their rights under the respective agreements, which may include the right to
terminate the agreement. To regain compliance with the agreement terms, it may be necessary to expend resources to regain compliance,
such as adding additional personnel or increasing expenditures to accelerate the development timelines. Such additional expenditures may
adversely impact our results of operations.

Regulatory compliance is
expensive, complex and uncertain,